CN1491105A - 新的改进释放的制剂 - Google Patents

新的改进释放的制剂 Download PDF

Info

Publication number
CN1491105A
CN1491105A CNA028049063A CN02804906A CN1491105A CN 1491105 A CN1491105 A CN 1491105A CN A028049063 A CNA028049063 A CN A028049063A CN 02804906 A CN02804906 A CN 02804906A CN 1491105 A CN1491105 A CN 1491105A
Authority
CN
China
Prior art keywords
multiparticleization
solid dispersion
dispersion preparation
discharge
skeleton pattern
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028049063A
Other languages
English (en)
Chinese (zh)
Inventor
A
A·尤波
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE0100478A external-priority patent/SE0100478D0/xx
Priority claimed from SE0100477A external-priority patent/SE0100477D0/xx
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CN1491105A publication Critical patent/CN1491105A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Steroid Compounds (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNA028049063A 2001-02-13 2002-02-08 新的改进释放的制剂 Pending CN1491105A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0100478A SE0100478D0 (sv) 2001-02-13 2001-02-13 Novel formulation
SE01004787 2001-02-13
SE01004779 2001-02-13
SE0100477A SE0100477D0 (sv) 2001-02-13 2001-02-13 Novel formulation

Publications (1)

Publication Number Publication Date
CN1491105A true CN1491105A (zh) 2004-04-21

Family

ID=26655389

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028049063A Pending CN1491105A (zh) 2001-02-13 2002-02-08 新的改进释放的制剂
CNA028049144A Pending CN1491104A (zh) 2001-02-13 2002-02-08 新型改进释放制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA028049144A Pending CN1491104A (zh) 2001-02-13 2002-02-08 新型改进释放制剂

Country Status (18)

Country Link
US (3) US20040067252A1 (enExample)
EP (2) EP1361868A1 (enExample)
JP (2) JP2004518708A (enExample)
KR (1) KR20040058103A (enExample)
CN (2) CN1491105A (enExample)
AT (1) ATE324871T1 (enExample)
AU (1) AU2002228579B2 (enExample)
BR (1) BR0206825A (enExample)
CA (2) CA2434542A1 (enExample)
DE (1) DE60211130T2 (enExample)
DK (1) DK1368006T3 (enExample)
ES (1) ES2261643T3 (enExample)
IL (1) IL157075A0 (enExample)
MX (1) MXPA03007092A (enExample)
NO (1) NO20033564L (enExample)
NZ (2) NZ526993A (enExample)
PT (1) PT1368006E (enExample)
WO (2) WO2002064118A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10026698A1 (de) 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
BR0314787A (pt) * 2002-09-28 2005-07-26 Mcneil Ppc Inc Forma de dosagem de liberação modificada
SE0301904D0 (sv) 2003-06-26 2003-06-26 Astrazeneca Ab Novel imidazopyridine compound II with therapeutic effect
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2007507425A (ja) * 2003-08-29 2007-03-29 ダイノゲン ファーマシューティカルズ，インコーポレイテッド 胃腸管運動障害を処置するために有用な組成物
WO2005053656A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate crystalline drug compositions containing preferably a poloxamer and a glyceride
WO2005053652A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Multiparticulate crystalline drug compositions containing a poloxamer and a glyceride
WO2005053639A2 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Controlled release multiparticulates formed with dissolution enhancers
AU2004294813A1 (en) * 2003-12-04 2005-06-16 Pfizer Products Inc. Spray-congeal process using an extruder for preparing multiparticulate azithromycin compositions containing preferably a poloxamer and a glyceride
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
MY191349A (en) * 2004-08-27 2022-06-17 Bayer Pharmaceuticals Corp New pharmaceutical compositions for the treatment of hyper-proliferative disorders
HRP20141001T1 (hr) 2006-03-16 2014-12-05 Euro-Celtique S.A. Farmaceutski sferoidi
JP2011516412A (ja) 2008-03-05 2011-05-26 ビカス セラピューティクス，エルエルシー 癌および粘膜炎の治療のための組成物および方法
EP2921486B1 (en) 2009-08-07 2017-09-27 American Life Science Pharmaceuticals, Inc. Compositions and methods for treating beta-amyloid related diseases
US20130165880A1 (en) 2010-09-17 2013-06-27 David T. Amos Antimicrobial disposable absorbent articles
WO2012070030A1 (en) * 2010-11-26 2012-05-31 University Of The Witwatersrand, Johannesburg A pharmaceutical composition
CA2859174C (en) 2011-12-12 2019-03-05 Orbis Biosciences, Inc. Sustained release particle formulations
US20130149383A1 (en) * 2011-12-12 2013-06-13 Cory Berkland Sustained release particle formulations of guaifenesin
EP3319595A4 (en) * 2015-06-30 2019-04-03 Kemin Industries, Inc. ENCAPSULATED ACTIVE SUBSTANCES FOR CONTROLLED ENTERAL ACTIVE COMPOSITION
US9889120B2 (en) 2016-01-14 2018-02-13 Vicus Therapeutics, Llc Combination drug therapies for cancer and methods of making and using them
DE102017108054A1 (de) 2017-04-13 2018-10-18 Natura Werk Gebr. Hiller GmbH & Co. KG Essbare Zusammensetzung zur Verdauungsförderung
WO2021142395A1 (en) 2020-01-10 2021-07-15 Consynance Therapeutics, Inc. Therapeutic combinations of drugs and methods of using them
US20250101427A1 (en) 2021-07-22 2025-03-27 The Regents Of The University Of California Compositions and methods for using purified human rna editing enzymes
WO2023184282A1 (en) * 2022-03-30 2023-10-05 Guizhou Sinorda Biomedicine Co., Ltd X842 formulation

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL248553A (enExample) * 1959-02-18
NL194389C (nl) * 1984-06-14 2002-03-04 Novartis Ag Werkwijze voor het bereiden van een vaste dispersie van een farmaceutisch actief middel dat een lage oplosbaarheid in water heeft, in een vaste matrix van een in water oplosbaar polyalkyleenglycol als drager.
US4629621A (en) * 1984-07-23 1986-12-16 Zetachron, Inc. Erodible matrix for sustained release bioactive composition
US5015479A (en) * 1987-02-02 1991-05-14 Seamus Mulligan Sustained release capsule or tablet formulation comprising a pharmaceutically acceptable dihydropyridine
US4956182A (en) * 1989-03-16 1990-09-11 Bristol-Myers Company Direct compression cholestyramine tablet and solvent-free coating therefor
US5405617A (en) * 1991-11-07 1995-04-11 Mcneil-Ppc, Inc. Aliphatic or fatty acid esters as a solventless carrier for pharmaceuticals
US5281420A (en) * 1992-05-19 1994-01-25 The Procter & Gamble Company Solid dispersion compositions of tebufelone
US5433951A (en) * 1993-10-13 1995-07-18 Bristol-Myers Squibb Company Sustained release formulation containing captopril and method
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
NZ270439A (en) * 1995-02-02 1996-04-26 Bernard Charles Sherman Solid slow release pharmaceutical composition: carrier is polyethylene glycol and hydrophilic gel-forming polymer
US5851555A (en) * 1997-08-15 1998-12-22 Fuisz Technologies Ltd. Controlled release dosage forms containing water soluble drugs
SE9801526D0 (sv) * 1998-04-29 1998-04-29 Astra Ab New compounds
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011000126A1 (zh) * 2009-06-29 2011-01-06 Liu Yu 脂溶性药物组合物、制备方法及其用途

Also Published As

Publication number Publication date
CA2434835A1 (en) 2002-08-22
DE60211130T2 (de) 2006-11-30
ES2261643T3 (es) 2006-11-16
JP2004518709A (ja) 2004-06-24
EP1368006B1 (en) 2006-05-03
CA2434542A1 (en) 2002-08-22
HK1059740A1 (en) 2004-07-16
IL157075A0 (en) 2004-02-08
NZ526994A (en) 2005-01-28
US20040067256A1 (en) 2004-04-08
BR0206825A (pt) 2004-02-25
US20080118560A1 (en) 2008-05-22
PT1368006E (pt) 2006-08-31
EP1368006A1 (en) 2003-12-10
NZ526993A (en) 2005-01-28
NO20033564D0 (no) 2003-08-12
AU2002228579B2 (en) 2006-07-27
DE60211130D1 (de) 2006-06-08
KR20040058103A (ko) 2004-07-03
MXPA03007092A (es) 2003-11-18
EP1361868A1 (en) 2003-11-19
WO2002064118A1 (en) 2002-08-22
CN1491104A (zh) 2004-04-21
WO2002064121A1 (en) 2002-08-22
US20040067252A1 (en) 2004-04-08
NO20033564L (no) 2003-10-02
JP2004518708A (ja) 2004-06-24
ATE324871T1 (de) 2006-06-15
DK1368006T3 (da) 2006-07-24

Similar Documents

Publication Publication Date Title
CN1491105A (zh) 新的改进释放的制剂
CN1298317C (zh) 坦洛新片剂
CN1190187C (zh) 差水溶性药物的固态溶液和分散液
CN1093758C (zh) 缓释粒状制剂及其制备方法
JP5147703B2 (ja) 経口投与でき、かつ活性成分の迅速な放出を有する固形医薬投与形態
CN1189171C (zh) 卡维地洛的亲水分子分散液
EP2136792B1 (en) Hot-melt micropellets
AU2002228579A1 (en) Novel modified released formulation
JP2006514044A (ja) 脱凝集微粒子を含む医薬製剤を製造する方法
CN1240132A (zh) 控制释放制剂
CN100345535C (zh) 胰岛素控释制剂及其方法
CN1509185A (zh) 医药用组合物
WO2008149338A2 (en) Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
CN1272785A (zh) 微渗透药物控释系统
KR20070116607A (ko) Ｏ-데스메틸벤라팍신 및 바제독시펜의 조합 산물 및 이의용도
WO2003082262A2 (en) Compositions of venlafaxine base
JP2004525887A (ja) 新規フェノフィブラート錠剤
CN1889932A (zh) 制备药用多颗粒的方法
CN1842331A (zh) 含有氨磺必利的新颖固体药物组合物
WO2024240116A1 (zh) 一种注射用药物缓释微球及其制备方法
CN1822818A (zh) 含有共沉淀剂形式的活性剂的颗粒
RU2696870C2 (ru) Пероральный препарат с замедленным высвобождением
HK1059740B (en) Novel modified released formulation
AU2002230344A1 (en) Novel modified release formulation

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication